LYNPARZA® (olaparib) | 10 Years Dedicated to Transforming Patient Care – LYNPARZA® (olaparib) | 10 Years
LYNPARZA ® (olaparib), a targeted poly (ADP-ribose) polymerase (PARP) inhibitor, is helping change the lives of many patients with cancers with certain DNA damage response (DDR) ‑ related mutations As the first FDA-approved PARP inhibitor, the approval of LYNPARZA was accompanied by an increase in the use of biomarker testing in treatment decision making. 1 Targeted therapies are cytotoxic to cancer cells with‑specific mutations, such as those in genes involved in the DNA damage response (DDR) pathway.
